Pozen, Inc. (POZN) Announces Trexima(TM) (Sumatriptan Succinate and Naproxen Sodium) Amended Response Accepted for Review by FDA  
11/1/2007 11:47:00 AM

CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ:POZN - News) announced today that its amended response to the FDA approvable letter for Trexima received on August 1, 2007 has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA has also notified POZEN that it considers the submission to be a complete, Class II response (six months) which could result in a new decision date of April 15, 2008.